BR0112360A - Método para aumentar a atividade da sintase de óxido nìtrico - Google Patents
Método para aumentar a atividade da sintase de óxido nìtricoInfo
- Publication number
- BR0112360A BR0112360A BR0112360-2A BR0112360A BR0112360A BR 0112360 A BR0112360 A BR 0112360A BR 0112360 A BR0112360 A BR 0112360A BR 0112360 A BR0112360 A BR 0112360A
- Authority
- BR
- Brazil
- Prior art keywords
- nitric oxide
- alkyl
- synthase activity
- ethers
- oxide synthase
- Prior art date
Links
- 230000001965 increasing effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 title abstract 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 4
- 150000005215 alkyl ethers Chemical class 0.000 abstract 2
- 150000002170 ethers Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical class *C#N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- SMYMDRJWEFCCCI-UHFFFAOYSA-N trichloro(trichloromethoxy)methane Chemical compound ClC(Cl)(Cl)OC(Cl)(Cl)Cl SMYMDRJWEFCCCI-UHFFFAOYSA-N 0.000 abstract 1
- WZEOZJQLTRFNCU-UHFFFAOYSA-N trifluoro(trifluoromethoxy)methane Chemical compound FC(F)(F)OC(F)(F)F WZEOZJQLTRFNCU-UHFFFAOYSA-N 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"MéTODOS PARA AUMENTAR A ATIVIDADE DA SINTASE DE óXIDO NìTRICO". Esta invenção proporciona processos para aumentar ou manter a atividade da sintase de óxido nítrico em mamíferos e produção de óxido nítrico compreendendo a administração de um composto das fórmulas: (I) em que Z é uma porção selecionada do grupo de (II) em que R~ 1~ é selecionado entre H, OH ou ésteres C~ 1~-C~ 12~ de éteres C~ 1~-C~ 12~ alquila dos mesmos, ou halogênios; ou éteres C~ 1~-C~ 4~ halogenados incluindo éter de trifluorometila e éter de triclorometila, R~ 2~, R~ 3~, R~ 4~, R~ 5~, e R~ 6~ são H, OH ou éteres C~ 1-C~ 12~ alquila dos mesmos, halogênios, ou éteres C~ 1~-C~ 4~ halogenados, ciano, C~ 1~-C~ 5~ alquila, ou trifluorometila, com a condição que, quando R~ 1~ é H, R~ 2~ não é OH; Y é a porção: (III) R~ 7~ e R~ 8~ sal alquila ou concatenados entre si para formar um anel opcionalmente substituído, contendo nitrogênio; ou um sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21618700P | 2000-07-06 | 2000-07-06 | |
| PCT/US2001/021083 WO2002003991A2 (en) | 2000-07-06 | 2001-06-29 | Use of substituted indole compounds for increasing nitric oxide synthase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0112360A true BR0112360A (pt) | 2003-05-06 |
Family
ID=22806070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0112360-2A BR0112360A (pt) | 2000-07-06 | 2001-06-29 | Método para aumentar a atividade da sintase de óxido nìtrico |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20020022617A1 (pt) |
| EP (1) | EP1296674A2 (pt) |
| JP (1) | JP2004502734A (pt) |
| CN (1) | CN1635885A (pt) |
| AU (1) | AU7178301A (pt) |
| BR (1) | BR0112360A (pt) |
| CA (1) | CA2414111A1 (pt) |
| MX (1) | MXPA02012890A (pt) |
| WO (1) | WO2002003991A2 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1531807A4 (en) * | 2002-06-13 | 2007-10-31 | Wyeth Corp | Bazedoxifene TREATMENT SCHEMES |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2006116157A2 (en) * | 2005-04-22 | 2006-11-02 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-iv inhibitors |
| WO2007118314A1 (en) * | 2006-04-13 | 2007-10-25 | Neuraxon, Inc. | 1,5 and 3,6- substituted indole compounds having nos inhibitory activity |
| EP2089047B1 (en) * | 2006-12-11 | 2012-11-14 | 3D Matrix, Inc. | Compositions and methods for cardiac tissue protection and regeneration |
| US10292971B2 (en) | 2015-10-01 | 2019-05-21 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs |
| ES2935125T3 (es) | 2015-12-09 | 2023-03-01 | Univ Illinois | Reguladores a la baja selectivos de los receptores de estrógenos con base en benzotiofeno |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| BR112018077136A2 (pt) | 2016-07-01 | 2019-04-30 | G1 Therapeutics, Inc. | composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis. |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| IL267795B2 (en) | 2017-01-06 | 2023-02-01 | G1 Therapeutics Inc | Combination therapy for the treatment of cancer |
| CA3052810A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CA3067873A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | Morphic forms of g1t38 and methods of manufacture thereof |
| CN107951034B (zh) * | 2017-12-01 | 2021-03-23 | 郑州拓洋生物工程有限公司 | 维生素泡腾制剂及其制备方法 |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
| EP3993785A4 (en) | 2019-07-07 | 2023-08-02 | Olema Pharmaceuticals, Inc. | ESTROGEN RECEPTOR ANTAGONIST SCHEMES |
| EP4076450A4 (en) | 2019-12-20 | 2024-01-10 | C4 Therapeutics, Inc. | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR EGFR DEGRADATION |
| EP4114392A4 (en) | 2020-03-05 | 2024-04-10 | C4 Therapeutics, Inc. | Compounds for targeted degradation of brd9 |
| CA3188313A1 (en) | 2020-08-05 | 2022-02-10 | C4 Therapeutics, Inc. | Compounds for targeted degradation of ret |
| WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
| CN120569388A (zh) | 2022-11-04 | 2025-08-29 | 百时美施贵宝公司 | Ret-ldd蛋白降解剂 |
| CN120530116A (zh) | 2022-11-04 | 2025-08-22 | 百时美施贵宝公司 | Ret-ldd蛋白抑制剂 |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW397821B (en) * | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| ATE206701T1 (de) * | 1996-04-19 | 2001-10-15 | American Home Prod | Östrogene verbindungen |
| US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| US5811437A (en) * | 1996-05-21 | 1998-09-22 | Eli Lilly And Company | Methods of increasing nitric oxide synthesis |
| US6172100B1 (en) * | 1997-04-30 | 2001-01-09 | Eli Lilly And Company | Antithrombotic agents |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| WO2001026651A2 (en) * | 1999-10-14 | 2001-04-19 | Endorecherche, Inc. | Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance |
| CO5271696A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
| CO5251465A1 (es) * | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
| RU2342145C2 (ru) * | 2000-01-28 | 2008-12-27 | Андорешерш, Инк. | Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами |
-
2001
- 2001-06-29 US US09/896,360 patent/US20020022617A1/en not_active Abandoned
- 2001-06-29 CA CA002414111A patent/CA2414111A1/en not_active Abandoned
- 2001-06-29 BR BR0112360-2A patent/BR0112360A/pt not_active Application Discontinuation
- 2001-06-29 EP EP01950824A patent/EP1296674A2/en not_active Withdrawn
- 2001-06-29 MX MXPA02012890A patent/MXPA02012890A/es unknown
- 2001-06-29 CN CNA018150926A patent/CN1635885A/zh active Pending
- 2001-06-29 JP JP2002508445A patent/JP2004502734A/ja active Pending
- 2001-06-29 WO PCT/US2001/021083 patent/WO2002003991A2/en not_active Application Discontinuation
- 2001-06-29 AU AU7178301A patent/AU7178301A/xx active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02012890A (es) | 2003-10-24 |
| WO2002003991A2 (en) | 2002-01-17 |
| CA2414111A1 (en) | 2002-01-17 |
| CN1635885A (zh) | 2005-07-06 |
| AU7178301A (en) | 2002-01-21 |
| EP1296674A2 (en) | 2003-04-02 |
| JP2004502734A (ja) | 2004-01-29 |
| US20020022617A1 (en) | 2002-02-21 |
| WO2002003991A3 (en) | 2002-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0112360A (pt) | Método para aumentar a atividade da sintase de óxido nìtrico | |
| MY130857A (en) | Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents | |
| ATE252097T1 (de) | N-heterocyclische derivate als nos inhibitoren | |
| AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
| NL350075I2 (pt) | ||
| CO5271665A1 (es) | (compuestos de pirrolo [2,3-d] pirimidina | |
| UY27740A1 (es) | Nuevos compuestos | |
| EA200201179A1 (ru) | Производные 2-аминокарбонил-9h-пурина | |
| MXPA03005464A (es) | Agentes antivirales. | |
| ES2161085T3 (es) | Formulaciones que contienen oxaliplatino. | |
| AR028948A1 (es) | Compuestos novedosos | |
| BR0112364A (pt) | Combinações de bisfosfonatos, agentes estrogênicos e opcionalmente estrogênios | |
| EA200300503A1 (ru) | Новые лекарственные композиции на основе солей тиотропия и солей салметерола | |
| BRPI0415053B8 (pt) | inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo | |
| BR0008753B1 (pt) | Composto de amida, processo para preparar um composto de amida, composição farmacêutica e uso de um composto de amida | |
| NZ513561A (en) | Pyridopyranoazepine derivatives, preparation and therapeutic use | |
| ATE359786T1 (de) | Camptothecin derivate | |
| DK0921787T3 (da) | Indgivelsesdosering af H+, K+ -ATPase-inhibitorer | |
| AR002711A1 (es) | Un compuesto de 2-carboxindol-3-substituido,un proceso para su preparacion, un nuevo compuesto intermediario para dicho proceso, el uso del compuesto parala fabricacion de un agente terapeutico y una composicion farmaceutica que comprende dicho compuesto. | |
| RS50229B (sr) | Analozi vitamina d3 | |
| ECSP034531A (es) | Derivados sustituidos de c-ciclohexilmetilamina | |
| AR029347A1 (es) | Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica | |
| BR0213731A (pt) | Compostos de silìcio | |
| BR0212353A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| PE20050393A1 (es) | Compuestos de benzopirano para uso en el tratamiento y la prevencion de afecciones relacionadas con la inflamacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |